ARTICLE | Clinical News
Simdax levosimendan: Phase III data
November 21, 2005 8:00 AM UTC
Data from the double-blind, international Phase III REVIVE II study in 600 patients showed that IV levosimendan plus standard therapy met the primary endpoint compared with placebo plus standard thera...